MediaPharma-Aegirbio R&D Agreement

Aegirbio AB has today signed a research & development agreement with MediaPharma Srl, an Italian biotech company focusing on novel drugs for the cure of cancer, and through this agreement Aegirbio intends to develop these drugs together with MediaPharma, in oncology and other areas. The unique characteristic of the cooperation is that Aegirbio’s Veritope technology […]

[...] Read More

Personalized medicine

At the present, one of the major problems in cancer treatment lies in the lack of suitable assays to select patients more likely to respond to a given anticancer therapy.

[...] Read More

Partnering

MediaPharma intends to advance its proprietary products portfolio to initial clinical safety and efficacy endpoints, then form strategic partnerships with companies that have the necessary commercialization infrastructures to best capture value.

[...] Read More

MediaPharma-Aegirbio R&D Agreement Personalized medicine Partnering

Ultime News

MediaPharma-Aegirbio R&D Agreement

Product pipeline

MediaPharma is committed to developing innovative products designed to safely and effectively treat patients with cancer and other severe diseases and improve their outcomes.

Product

Description

Status

MP-EV20-ADC

Anti-HER3 Antibody-Drug Conjugate

Preclinical

MP-EV20-⁸⁹Zr	EV20 conjugated as an immune-PET tracer	Preclinical
MP-1959	Anti-Gal-3BP Antibody	Preclinical
MP-1959-ADC	Anti-Gal-3BP Antibody-Drug Conjugate	Preclinical

MediaPharma-Aegirbio R&D Agreement

Personalized medicine

Partnering

Highlights

Ultime News

Product pipeline

Company

R&D

Careers

Business